CMBA
ATRA icon

C.M. Bidwell & Associates’s Atara Biotherapeutics ATRA Stock Holding History

C.M. Bidwell & Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-380
Closed -$195K – 326
2017
Q1 		$195K Buy
+380
New +$157K 0.04% 160

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

C.M. Bidwell & Associates's ATRA Position: Q2 2017 in Review

C.M. Bidwell & Associates sold out of Atara Biotherapeutics (ATRA) in Q2 2017, closing a stake of 380 shares — an estimated $195K sold.

C.M. Bidwell & Associates first reported a position in ATRA in Q1 2017 and held it in 1 quarter. The position peaked at $195K in Q1 2017. 84 funds tracked by Wall St. Rank hold ATRA as of Q2 2017.

  • C.M. Bidwell & Associates reported no remaining Atara Biotherapeutics position as of Q2 2017 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 380 Atara Biotherapeutics shares in Q2 2017, an estimated $195K.
  • C.M. Bidwell & Associates first reported a position in Atara Biotherapeutics in Q1 2017 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Atara Biotherapeutics position peaked at $195K in Q1 2017.
  • 84 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2017.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2017, filed 14 Aug 2017.